Dr. Reddy's Laboratories Limited RDDA.F Stock
Dr. Reddy's Laboratories Limited Price Chart
Dr. Reddy's Laboratories Limited RDDA.F Financial and Trading Overview
Dr. Reddy's Laboratories Limited stock price | 67 EUR |
Previous Close | 53 EUR |
Open | 54 EUR |
Bid | 0 EUR x 20000 |
Ask | 0 EUR x 20000 |
Day's Range | 54 - 54.5 EUR |
52 Week Range | 47 - 57 EUR |
Volume | 4 EUR |
Avg. Volume | 16 EUR |
Market Cap | 9.05B EUR |
Beta (5Y Monthly) | 0.230136 |
PE Ratio (TTM) | 17.524117 |
EPS (TTM) | 3.5 EUR |
Forward Dividend & Yield | 0.44 (0.85%) |
Ex-Dividend Date | July 7, 2023 |
1y Target Est | 77.85 EUR |
RDDA.F Valuation Measures
Enterprise Value | 4.89B EUR |
Trailing P/E | 17.524117 |
Forward P/E | 22.336065 |
PEG Ratio (5 yr expected) | -18.52 |
Price/Sales (ttm) | 0.036821563 |
Price/Book (mrq) | 0.23470238 |
Enterprise Value/Revenue | 0.02 |
Enterprise Value/EBITDA | 0.074 |
Trading Information
Dr. Reddy's Laboratories Limited Stock Price History
Beta (5Y Monthly) | 0.230136 |
52-Week Change | 3.88% |
S&P500 52-Week Change | 20.43% |
52 Week High | 57 EUR |
52 Week Low | 47 EUR |
50-Day Moving Average | 52.8 EUR |
200-Day Moving Average | 51.98 EUR |
RDDA.F Share Statistics
Avg. Volume (3 month) | 16 EUR |
Avg. Daily Volume (10-Days) | 25 EUR |
Shares Outstanding | 166.12M |
Float | 710.14M |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 10.47% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 40 |
Trailing Annual Dividend Yield | 75.47% |
5 Year Average Dividend Yield | 65.00% |
Payout Ratio | 0.1112 |
Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | March 31, 2023 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | March 31, 2024 |
Profitability
Profit Margin | 18.32% |
Operating Margin (ttm) | 21.63% |
Gross Margin | 56.67% |
EBITDA Margin | 26.77% |
Management Effectiveness
Return on Assets (ttm) | 10.81% |
Return on Equity (ttm) | 21.38% |
Income Statement
Revenue (ttm) | 245.88B EUR |
Revenue Per Share (ttm) | 247.31 EUR |
Quarterly Revenue Growth (yoy) | 15.80% |
Gross Profit (ttm) | N/A |
EBITDA | 65.83B EUR |
Net Income Avi to Common (ttm) | 45.07B EUR |
Diluted EPS (ttm) | 3.11 |
Quarterly Earnings Growth (yoy) | 996.19% |
Balance Sheet
Total Cash (mrq) | 61.8B EUR |
Total Cash Per Share (mrq) | 62.12 EUR |
Total Debt (mrq) | 13.47B EUR |
Total Debt/Equity (mrq) | 5.83 EUR |
Current Ratio (mrq) | 2.411 |
Book Value Per Share (mrq) | 232.20898 |
Cash Flow Statement
Operating Cash Flow (ttm) | 58.87B EUR |
Levered Free Cash Flow (ttm) | 26.61B EUR |
Profile of Dr. Reddy's Laboratories Limited
Country | Germany |
State | N/A |
City | Hyderabad |
Address | 8-2-337, Road No. 3 |
ZIP | 500034 |
Phone | 91 40 4900 2900 |
Website | https://www.drreddys.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Q&A For Dr. Reddy's Laboratories Limited Stock
What is a current RDDA.F stock price?
Dr. Reddy's Laboratories Limited RDDA.F stock price today per share is 67 EUR.
How to purchase Dr. Reddy's Laboratories Limited stock?
You can buy RDDA.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Dr. Reddy's Laboratories Limited?
The stock symbol or ticker of Dr. Reddy's Laboratories Limited is RDDA.F.
Which industry does the Dr. Reddy's Laboratories Limited company belong to?
The Dr. Reddy's Laboratories Limited industry is Drug Manufacturers-Specialty & Generic.
How many shares does Dr. Reddy's Laboratories Limited have in circulation?
The max supply of Dr. Reddy's Laboratories Limited shares is 169.15M.
What is Dr. Reddy's Laboratories Limited Price to Earnings Ratio (PE Ratio)?
Dr. Reddy's Laboratories Limited PE Ratio is 19.14285700 now.
What was Dr. Reddy's Laboratories Limited earnings per share over the trailing 12 months (TTM)?
Dr. Reddy's Laboratories Limited EPS is 3.5 EUR over the trailing 12 months.
Which sector does the Dr. Reddy's Laboratories Limited company belong to?
The Dr. Reddy's Laboratories Limited sector is Healthcare.